Document Detail


A critical review of the use of carvedilol in ischemic heart disease.
MedLine Citation:
PMID:  23061698     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
β-Adrenergic receptor antagonists (β-blockers) have been recognized for their cardioprotective properties, prompting use of these pharmacologic agents to become more mainstream in acute myocardial infarction (AMI) and congestive heart failure (CHF). Despite their popularity as a class, the ability to protect the myocardium varies significantly between different agents. Carvedilol is a non-selective β-blocker with α₁-adrenergic receptor antagonism properties. It is unique among β-blockers because in addition to improving exercise tolerance and its anti-ischemic properties secondary to a reduction in heart rate and myocardial contractility, carvedilol exerts other beneficial effects including: antioxidant effects; reduction in neutrophil infiltration; apoptosis inhibition; reduction of vascular smooth muscle migration; and improvement of myocardial remodeling post-AMI. These properties, documented in animal models and subsequent clinical trials, are consistent with established evidence demonstrating decreased morbidity and mortality in patients with CHF and post-AMI. This article reviews the role of carvedilol compared with other β-blockers in the treatment of CHF and post-AMI management.
Authors:
Carol Chen-Scarabelli; Louis Saravolatz; Yahya Murad; Wen-Shi Shieh; Waqas Qureshi; Justin Di Rezze; Rodeo Abrencillo; Tova Gardin; Umesh K Gidwani; Louis Saravolatz; Giuseppe Faggian; Tiziano M Scarabelli
Related Documents :
195508 - Pathophysiology of myocardial infarction.
24282438 - Effectiveness of panax ginseng on acute myocardial ischemia reperfusion injury was abol...
10949908 - Myocardial postischemic injury is reduced by polyadpripose polymerase-1 gene disruption.
15454858 - P38 alpha mitogen-activated protein kinase inhibition improves cardiac function and red...
17600648 - Noninvasive coronary angiography using 64-slice spiral computed tomography in an unsele...
22989728 - Protective effects of nhe1 inhibition with sabiporide in an experimental model of asphy...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of cardiovascular drugs : drugs, devices, and other interventions     Volume:  12     ISSN:  1179-187X     ISO Abbreviation:  Am J Cardiovasc Drugs     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-27     Completed Date:  2013-04-29     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  100967755     Medline TA:  Am J Cardiovasc Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  391-401     Citation Subset:  IM    
Affiliation:
Center for Heart and Vessel Preclinical Studies, St John Hospital and Medical Center, Wayne State University School of Medicine, Detroit, MI 48236, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use*
Angina, Stable / drug therapy
Animals
Anti-Arrhythmia Agents / therapeutic use
Antioxidants / therapeutic use
Arrhythmias, Cardiac / drug therapy,  prevention & control
Carbazoles / therapeutic use*
Cardiotonic Agents / therapeutic use*
Evidence-Based Medicine
Humans
Myocardial Infarction / drug therapy,  prevention & control
Myocardial Ischemia / drug therapy*
Propanolamines / therapeutic use*
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Anti-Arrhythmia Agents; 0/Antioxidants; 0/Carbazoles; 0/Cardiotonic Agents; 0/Propanolamines; 0K47UL67F2/carvedilol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rules for Identifying Potentially Reactive or Promiscuous Compounds.
Next Document:  Association between sociodemographic status and antiepileptic drug prescriptions in children with ep...